

## Blood-Stream Infection (CDC)

---

**From:** Fink, David [David.Fink@Covidien.com]  
**Sent:** Thursday, December 03, 2009 9:50 PM  
**To:** Blood-Stream Infection (CDC)  
**Subject:** Draft CDC Guidelines for the prevention of CRBSI's  
**Follow Up Flag:** Follow up  
**Flag Status:** Red

To the Center for Disease Control,

I would like to provide comment to the draft guidelines for the prevention of Catheter Related Bloodstream Infections currently being considered for improving patient outcomes.

Covidien has been marketing antimicrobial wound care dressings since October 2001; these products are indicated for the use on acute wounds, chronic wounds, and surgical wounds. Covidien antimicrobial wound care dressings are intended to prevent bacterial penetration thru the dressing and bacterial colonization within the dressing. The antimicrobial agent used to treat these dressings is Polyhexamethylene Biguanide (PHMB) in a 0.2% concentration. That PHMB antiseptic is in the same biguanide family as CHG with demonstrated efficacy against an equally [\[Wing1\]](#) broad range of bacteria.

In this time period, Covidien has successfully distributed over 100,000,000 antimicrobial dressings, primarily gauze based but include foam based sponge dressings, into the field in a broad range of healthcare settings. One major focus of use is in the reduction of surgical site infections with a goal of providing an antimicrobial barrier around the surgical site to prevent bacterial contamination through the dressing. Institutions using this product have documented reductions in infection rates ranging from 24 – 86%. [\[Wing2\]](#)

Covidien respectfully requests amendment of the proposed language in the draft guidelines for CRBSI Section 11 to read as follows:

**11. Use an antimicrobial-impregnated sponge dressing for temporary short-term catheters in patients older than 2 months of age, if the CRBSI rate is higher than the institutional goal, despite adherence to basic CRBSI prevention measures, including education and training, use of chlorhexidine for skin antisepsis, and MSB [22, 156-158]. Category 1B.**

Respectfully Submitted,

David Fink  
 Director of Research and Development  
 Wound Care  
 Covidien  
 15 Hampshire Street  
 Mansfield, MA 02048  
 508-261-8464  
[David.Fink@Covidien.com](mailto:David.Fink@Covidien.com)

---

[\[Wing1\]](#) Has this been proven? Are there any microbe that are more resistant to one over the other?

[\[Wing2\]](#)